In a bid to strengthen its footprint in overseas market, drug major Lupin is scouting for acquisition opportunities in the US market, especially in inhalers and injectables segments. The company continues to be on the lookout for meaningful targets, be it brands or technology companies, in inhalation, complex injectables and skin diseases segments.
Moreover, the Mumbai-based firm is aiming to grow at around 25 per cent in the world’s largest drug market. Further, the company remains the 5th largest and fastest growing top five generic players in the U.S. for the third year now.
Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded and generic formulations and APIs globally.
